Our top pick for
Surgery Partners Inc is a medical care facilities business based in the US. Surgery Partners shares (SGRY) are listed on the NASDAQ and all prices are listed in US Dollars. Surgery Partners employs 9,100 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$41.97|
|52-week range||$20.87 - $69.58|
|50-day moving average||$43.75|
|200-day moving average||$51.57|
|Wall St. target price||$63.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-1.18%|
|1 month (2021-09-27)||-0.97%|
|3 months (2021-07-27)||-24.26%|
|6 months (2021-04-27)||-15.13%|
|1 year (2020-10-26)||91.64%|
|2 years (2019-10-25)||391.45%|
|3 years (2018-10-26)||228.66%|
|5 years (2016-10-26)||128.47%|
Valuing Surgery Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Surgery Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Surgery Partners's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.66. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Surgery Partners's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Surgery Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $373.7 million.
The EBITDA is a measure of a Surgery Partners's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.1 billion|
|Operating margin TTM||13.01%|
|Gross profit TTM||$379.8 million|
|Return on assets TTM||3.14%|
|Return on equity TTM||1.92%|
|Market capitalisation||$3.6 billion|
TTM: trailing 12 months
There are currently 1.8 million Surgery Partners shares held short by investors – that's known as Surgery Partners's "short interest". This figure is 1.5% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Surgery Partners shares can be evaluated.
Surgery Partners's "short interest ratio" (SIR) is the quantity of Surgery Partners shares currently shorted divided by the average quantity of Surgery Partners shares traded daily (recently around 384175.0533049). Surgery Partners's SIR currently stands at 4.69. In other words for every 100,000 Surgery Partners shares traded daily on the market, roughly 4690 shares are currently held short.
However Surgery Partners's short interest can also be evaluated against the total number of Surgery Partners shares, or, against the total number of tradable Surgery Partners shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Surgery Partners's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Surgery Partners shares in existence, roughly 20 shares are currently held short) or 0.0334% of the tradable shares (for every 100,000 tradable Surgery Partners shares, roughly 33 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Surgery Partners.
Find out more about how you can short Surgery Partners stock.
We're not expecting Surgery Partners to pay a dividend over the next 12 months.
Over the last 12 months, Surgery Partners's shares have ranged in value from as little as $20.87 up to $69.58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Surgery Partners's is 3.1593. This would suggest that Surgery Partners's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Surgery Partners, Inc. , through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through Surgical Facility Services and Ancillary Services segments. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2020, it owned or operated a portfolio of 127 surgical facilities, including 110 ambulatory surgical centers and 17 surgical hospitals in 30 states. Surgery Partners, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.